Percentage of Participants With Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma · Source last updated 2025-01-13
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Up to 30 days after completion of study treatment
What was measured
Grade 3 and higher toxicities will be descriptively summarized.
Analysis population: Three ineligible patients were excluded from this analysis. Two patients who did not receive therapy were also excluded from this analysis.
Groups in this outcome
Stage 2/3 Patients
Patients with orbital disease (including microscopic trans-scleral invasion seen on enucleation pathology), optic nerve margin (+), and/or regional nodal disease, but no other sites of metastases. Stage 2 and 3 patients will receive Induction chemotherapy and External Beam Radiation Therapy, but will not receive Consolidation therapy (High-Dose Chemotherapy with Stem Cell Rescue).
Stage 4a Patients
Patients with overt distant metastatic disease (such as bone, bone marrow, and/or liver) but no detectable CNS involvement. Patients will receive Induction chemotherapy, Stem Cell Harvesting, Consolidation with Stem Cell Rescue, and depending on response to Induction chemotherapy, possibly External Beam Radiation Therapy.
Stage 4b Patients
Patients with overt CNS involvement (brain parenchyma, leptomeninges and CSF cytology). Patients with trilateral retinoblastoma will be included. Patients will receive Induction chemotherapy, Stem Cell Harvesting, Consolidation with Stem Cell Rescue, and depending on response to Induction chemotherapy, possibly External Beam Radiation Therapy.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Stage 2/3 Patients
18
Stage 4a Patients
18
Stage 4b Patients
19
Reported measurements
Abdominal pain
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Acute kidney injury
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Alanine aminotransferase increased
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
16.7
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Anemia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Anorexia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
33.3
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
15.8
Not reported
Not reported
Not reported
Not reported
Apnea
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Aspartate aminotransferase increased
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Catheter related infection
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Dehydration
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
10.5
Not reported
Not reported
Not reported
Not reported
Depressed level of consciousness
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Diarrhea
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
16.7
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Encephalopathy
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Enterocolitis
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Enterocolitis infectious
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Esophagitis
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Febrile neutropenia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
55.6
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
55.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
36.8
Not reported
Not reported
Not reported
Not reported
Fever
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
GGT increased
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Gastric hemorrhage
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Hearing impaired
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Hypermagnesemia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Hypertension
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Hypoalbuminemia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Hypocalcemia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
10.5
Not reported
Not reported
Not reported
Not reported
Hypoglycemia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Hypokalemia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
27.8
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
16.7
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
21.1
Not reported
Not reported
Not reported
Not reported
Hypomagnesemia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
10.5
Not reported
Not reported
Not reported
Not reported
Hyponatremia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
15.8
Not reported
Not reported
Not reported
Not reported
Hypophosphatemia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
22.2
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
10.5
Not reported
Not reported
Not reported
Not reported
Hypotension
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Hypoxia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
2.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Infections and infestations - Other, specify
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
27.8
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
33.3
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
21.1
Not reported
Not reported
Not reported
Not reported
Lower gastrointestinal hemorrhage
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Lung infection
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
16.7
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Lymphocyte count decreased
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Mucositis oral
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
27.8
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Nausea
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
16.7
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Nervous system disorders - Other, specify
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
10.5
Not reported
Not reported
Not reported
Not reported
Neutrophil count decreased
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Oral pain
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Pain
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Peripheral motor neuropathy
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Pharyngeal mucositis
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Platelet count decreased
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Pneumonitis
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Rectal pain
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Seizure
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Sepsis
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Sinus tachycardia
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Sinusitis
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Skin infection
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Upper respiratory infection
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
0
Not reported
Not reported
Not reported
Not reported
Vomiting
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
11.1
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
22.2
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
White blood cell decreased
Values in percentage of participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Stage 2/3 Patients
5.6
Not reported
Not reported
Not reported
Not reported
Stage 4a Patients
0
Not reported
Not reported
Not reported
Not reported
Stage 4b Patients
5.3
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
5.6
group Id
OG002
value
0
title
Abdominal pain
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
5.6
group Id
OG002
value
0
title
Acute kidney injury
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
16.7
group Id
OG002
value
5.3
title
Alanine aminotransferase increased
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
5.3
title
Anemia
categories
measurements
group Id
OG000
value
11.1
group Id
OG001
value
33.3
group Id
OG002
value
15.8
title
Anorexia
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
5.3
title
Apnea
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
11.1
group Id
OG002
value
5.3
title
Aspartate aminotransferase increased
categories
measurements
group Id
OG000
value
11.1
group Id
OG001
value
0
group Id
OG002
value
0
title
Catheter related infection
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
11.1
group Id
OG002
value
10.5
title
Dehydration
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
5.3
title
Depressed level of consciousness
categories
measurements
group Id
OG000
value
5.6
group Id
OG001
value
16.7
group Id
OG002
value
0
title
Diarrhea
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
5.3
title
Encephalopathy
denoms
counts
group Id
OG000
value
18
group Id
OG001
value
18
group Id
OG002
value
19
units
Participants
description
Grade 3 and higher toxicities will be descriptively summarized.
groups
description
Patients with orbital disease (including microscopic trans-scleral invasion seen on enucleation pathology), optic nerve margin (+), and/or regional nodal disease, but no other sites of metastases. Stage 2 and 3 patients will receive Induction chemotherapy and External Beam Radiation Therapy, but will not receive Consolidation therapy (High-Dose Chemotherapy with Stem Cell Rescue).
id
OG000
title
Stage 2/3 Patients
description
Patients with overt distant metastatic disease (such as bone, bone marrow, and/or liver) but no detectable CNS involvement. Patients will receive Induction chemotherapy, Stem Cell Harvesting, Consolidation with Stem Cell Rescue, and depending on response to Induction chemotherapy, possibly External Beam Radiation Therapy.
id
OG001
title
Stage 4a Patients
description
Patients with overt CNS involvement (brain parenchyma, leptomeninges and CSF cytology). Patients with trilateral retinoblastoma will be included. Patients will receive Induction chemotherapy, Stem Cell Harvesting, Consolidation with Stem Cell Rescue, and depending on response to Induction chemotherapy, possibly External Beam Radiation Therapy.
id
OG002
title
Stage 4b Patients
param Type
NUMBER
population Description
Three ineligible patients were excluded from this analysis. Two patients who did not receive therapy were also excluded from this analysis.
reporting Status
POSTED
time Frame
Up to 30 days after completion of study treatment
title
Percentage of Participants With Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
Triangle